Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of itsin vivosynergism with gemcitabine, in pancreatic adenocarcinoma mouse models

(2016) María Virtudes Céspedes et al.   Disease Models & Mechanisms

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells

(2016) G. Santamaria Nunez et al.   MOLECULAR CANCER THERAPEUTICS

Abstract P3-13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial:

(2015) Judit Balmaña et al.   CANCER RESEARCH

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions

(2015) Laird Cameron et al.   DRUGS

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Thomas J. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

(2015) Min-Young Lee   WORLD JOURNAL OF GASTROENTEROLOGY

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

(2015) Jiabei He et al.   Scientific Reports

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

(2014) M. E. Elez et al.   CLINICAL CANCER RESEARCH

47 Lurbinectedin (PM01183) specifically targets RNA Pol II for degradation via the proteasome pathway in a transcription and TC-NER dependent fashion

(2014) G. Santamaria et al.   EUROPEAN JOURNAL OF CANCER

23 Phase I study of lurbinectedin (PM01183) administered on days (D) 1 & 8 every 3 weeks (q3wk) in patients (pts) with solid tumors

(2014) M.J. Ratain et al.   EUROPEAN JOURNAL OF CANCER

223 Lurbinectedin (PM01183) Synergizes with Gemcitabine in NSCLC, Ovarian and Pancreas Tumor Xenografts

(2012) R. Mangues et al.   EUROPEAN JOURNAL OF CANCER

Identification and manipulation of tumor associated macrophages in human cancers

(2011) Moniek Heusinkveld et al.   Journal of Translational Medicine

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

(2011) D. G. Soares et al.   MOLECULAR CANCER THERAPEUTICS

Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations

(2011) Juan A. Bueren-Calabuig et al.   NUCLEIC ACIDS RESEARCH

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

(2010) JFM Leal et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

(2008) Wells A. Messersmith et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer

(2008) T. E. Stinchcombe et al.   ONCOLOGIST